Published online Aug 28, 2025. doi: 10.4329/wjr.v17.i8.109373
Revised: May 21, 2025
Accepted: July 22, 2025
Published online: August 28, 2025
Processing time: 112 Days and 0.9 Hours
Lymph node metastasis (LNM) is a key prognostic factor in pancreatic cancer (PC). Accurate preoperative prediction of LNM remains challenging. Radiomics offers a noninvasive method to extract quantitative imaging features that may aid in predicting LNM.
To investigate the potential value of a computed tomography (CT)-based radio
A retrospective analysis was performed on 168 pathologically confirmed PC patients who underwent contrast-enhanced-CT. Among them, 107 cases had no LNM, while 61 cases had confirmed LNM. These patients were randomly divided into a training cohort (n = 135) and a validation cohort (n = 33). A total of 792 ra
Six radiomics features from the arterial phase and nine from the portal venous phase were selected. The Radscore model demonstrated strong predictive performance for LNM in both the training and test cohorts, with AUC values ranging from 0.86 to 0.94, sensitivity between 66.7% and 91.7%, specificity from 71.4% to 100.0%, accuracy between 78.8% and 91.1%, PPV ranging from 64.7% to 100.0%, and negative predictive value between 84.0% and 93.8%. No significant differences in AUC values were observed between the arterial and portal venous phases in either the training or test set.
The preoperative CT-based radiomics model exhibited robust predictive capability for identifying LNM in PC.
Core Tip: A preoperative computed tomography-based radiomics model demonstrates high accuracy in predicting lymph node metastasis (LNM) in pancreatic cancer, providing a non-invasive tool to guide personalized treatment. Unlike traditional imaging, radiomics detects microstructural patterns invisible to the human eye, enhancing LNM detection irrespective of phase (arterial vs portal). Clinically, this model could refine preoperative staging, identify candidates for curative surgery, or prioritize neoadjuvant chemotherapy for high-risk patients, optimizing outcomes. Prospective validation is needed for broader adoption.